A study on experiences of patients undergoing injection in back part of their eye.
- Conditions
- Health Condition 1: H350- Background retinopathy and retinalvascular changes
- Registration Number
- CTRI/2019/01/016907
- Lead Sponsor
- Aravind Eye Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Patients with visual acuity better than 6/60 undergoing intravitreal anti VEGF [vascular endothelial growth factor] for following pathologies.
2.Retinal Venous Occlusion Diseases [RVOD].
3.Diabetic Macular Edema [DME].
4.Age related Macular Degeneration [AMD].
5.Polypoidal Choroidal Vasculopathy [PCV].
1.Patients planned for vitrectomy after anti VEGF[vascular endothelial growth factor].
2.Neo Vascular Glaucoma [NVG].
3.Uncontrolled hypertension (>= 160 mm Hg systolic or >= 100 mm Hg diastolic), with or without anti-hypertensive medications.
4.Patients consuming drugs that influence cardiac rate and rhythm (like Beta-blockers).
5.Uncontrolled Diabetes Mellitus (FBS >= 180 mg/dl), despite medications.
6.Patients with dementia, hearing impairment, speech disorder, mental retardation, or patients with any psychiatric ailments, or on any psychiatric medications.
7.Patients with Uveitis.
8.Patients with ocular manifestations of diabetes other than retinopathy-Diabetic neuropathy.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1)To quantitatively describe the patientsâ?? experiences by determining their opinion [distress level] on the whole injection processTimepoint: 1 year from starting day of study.
- Secondary Outcome Measures
Name Time Method 2)To assess subjectively (by means of questionnaire) and objectively(by measuring vital signs- pre injection, during injection, post injection) visual experience of patients undergoing intravitreal anti vascular endothelial growth factor.Timepoint: 1 year from starting day of study.